Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Current Pharmaceutical Biotechnology
Title:Progress of Biological Agents on Psoriatic Arthritis
Volume: 15 Issue: 6
Author(s): Yan Li, Dashan Wang, Yantang Wang and Guixiu Shi
Affiliation:
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Export Options
About this article
Cite this article as:
Li Yan, Wang Dashan, Wang Yantang and Shi Guixiu, Progress of Biological Agents on Psoriatic Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150227
DOI https://dx.doi.org/10.2174/138920101506140910150227 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): Still an Obscure Disease
Central Nervous System Agents in Medicinal Chemistry Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Biologic and Novel Therapy of the Inflammatory Bowel Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry Protective Effects of Heme-Oxygenase Expression in Cyclosporine A - Induced Injury
Current Neurovascular Research White Matter Integrity in Subcortical Vascular Cognitive Impairment: A Multimodal Structural MRI Study
Current Alzheimer Research MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets